A subgroup analysis of the MONICA study: a 12-month, open-label study of add-on montelukast treatment in asthma patients (vol 47, pg 986, 2010)

被引：0
|
作者：
Virchow, J. Christian
机构：
来源：
JOURNAL OF ASTHMA | 2011年 / 48卷 / 06期
关键词：
D O I：
10.3109/02770903.2011.589639
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：650 / 652
页数：3
相关论文
共 50 条
  • [41] An open-label, self-controlled study of topiramate as add-on therapy with lower dose for treatment of refractory epilepsy
    Yi, YH
    Yang, SQ
    Liao, WP
    Deng, YH
    Li, BM
    Pan, Y
    Pu, SX
    He, XS
    Lu, XF
    EPILEPSIA, 2005, 46 : 275 - 276
  • [42] FELBAMATE IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME - RESULTS OF A 12-MONTH OPEN-LABEL STUDY FOLLOWING A RANDOMIZED CLINICAL-TRIAL
    DODSON, WE
    EPILEPSIA, 1993, 34 : S18 - S24
  • [43] Patient functional status, safety, and tolerability of modafinil in a 12-month open-label study in patients with chronic shift work sleep disorder
    Rosenberg, R
    Corser, B
    SLEEP, 2004, 27 : 57 - 58
  • [44] Re: The Efficacy and Safety of Degarelix: A 12-Month, Comparative, Randomized, Open-Label, Parallel-Group Phase III Study in Patients with Prostate Cancer (vol 55, pg 1488, 2009)
    Persson, Bo-Eric
    EUROPEAN UROLOGY, 2009, 56 (05) : E40 - E40
  • [45] Additional Results From a 12-Month Open-Label Safety Study of Lumateperone (ITI-007) in Patients With Stable Symptoms of Schizophrenia
    Satlin, Andrew
    Vanover, Kimberly
    Durgam, Suresh
    Mates, Sharon
    Davis, Robert
    Correll, Christoph
    NEUROPSYCHOPHARMACOLOGY, 2019, 44 (SUPPL 1) : 493 - 494
  • [46] 12-month interim results of a multicentre open-label study of the InnFocus MicroShunt® Glaucoma Drainage System in patients with primary open-angle glaucoma
    Shaarawy, Tarek M.
    Aptel, Florent
    Beckers, Henny J.
    Webers, Carroll A. B.
    Bluwol, Elisa
    Martinez-de-la-Casa, Jose M.
    Garcia-Feijoo, Julian
    Lachkar, Yves
    Mendez-Hernandez, Carmen D.
    Riss, Isabelle
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
  • [47] Growth Effects of Methylphenidate Among Childhood Cancer Survivors: A 12-Month Case-Matched Open-Label Study
    Jasper, Bruce W.
    Conklin, Heather M.
    Lawford, Joanne
    Morris, E. Brannon
    Howard, Scott C.
    Wu, Shengjie
    Xiong, Xiaoping
    Shelso, John
    Khan, Raja B.
    PEDIATRIC BLOOD & CANCER, 2009, 52 (01) : 39 - 43
  • [48] Long-term efficacy and safety of once-monthly Risperidone ISM® in the treatment of schizophrenia: Results from a 12-month open-label extension study (vol 239, pg 83, 2022)
    Filts, Yuriy
    Litman, Robert E.
    Martinez, Javier
    Anta, Lourdes
    Naber, Dieter
    Correll, Christoph U.
    SCHIZOPHRENIA RESEARCH, 2022, 246 : 258 - 259
  • [49] ADHD treatment with once-daily OROS methylphenidate: Interim 12-month results from a long-term open-label study
    Wilens, T
    Pelham, W
    Stein, M
    Conners, CK
    Abikoff, H
    Atkins, M
    August, G
    Greenhill, L
    McBurnett, K
    Palumbo, D
    Swanson, J
    Wolraich, M
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2003, 42 (04): : 424 - 433
  • [50] A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study
    Botson, John
    Peloso, Paul
    Obermeyer, Katie
    LaMoreaux, Brian
    Zhao, Lin
    Weinblatt, Michael
    Peterson, Jeff
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
12345